Rising plasminogen activator inhibitor-1 and hypoadiponectinemia characterize the cardiometabolic biomarker profile of women with recent gestational diabetes
Open Access
- 9 October 2018
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 17 (1) , 133
Abstract
Gestational diabetes (GDM) and milder gestational impaired glucose tolerance (GIGT) identify women at risk of developing type 2 diabetes and cardiovascular disease later in life. Accordingly, the postpartum years after gestational dysglycemia can provide insight into early events in the natural history of these disorders. We thus sought to prospectively evaluate the relationship between gestational glucose tolerance and emerging cardiometabolic biomarkers [adiponectin, chemerin, retinol-binding protein-4 (RBP-4), C-reactive protein (CRP), plasminogen activator inhibitor-1 (PAI-1)] at both 1- and 3-years postpartum in a cohort reflecting the full spectrum of gestational dysglycemia (from normal to GIGT to GDM). Three-hundred-and-thirty-nine women completed a glucose challenge test (GCT) and oral glucose tolerance test (OGTT) in pregnancy, which identified 4 gestational glucose tolerance groups: GDM (n = 105); GIGT (n = 59); abnormal GCT with normal OGTT (n = 99); and normal GCT with normal OGTT (n = 76). At 1- and 3-years postpartum, the women underwent repeat OGTT with measurement of biomarkers (adiponectin/chemerin/RBP-4/CRP/PAI-1). Serum adiponectin was lower in women with GDM and GIGT at both 1-year and 3-years (both P ≤ 0.002), whereas chemerin, RBP-4, CRP and PAI-1 showed no differences across the 4 groups. Importantly, the change in PAI-1 between 1- and 3-years progressively increased from the normal GCT group to the abnormal GCT group to GIGT to GDM (P = 0.03). Indeed, both GDM (t = 2.98, P = 0.003) and GIGT (t = 2.14, P = 0.03) independently predicted an increase in PAI-1 from 1- to 3-years postpartum. Hypoadiponectinemia and rising PAI-1 over time are early features of the cardiometabolic biomarker profile of women with recent gestational dysglycemia.Keywords
Funding Information
- Canadian Insititutes of Health Research (MOP-84206)
- Diabetes Canada (CDA-OG-3-15-4924-RR)
- Boehringer Ingelheim (investigator-initiated study)
- Sun Life Financial (donation)
This publication has 36 references indexed in Scilit:
- The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: the Insulin Resistance Atherosclerosis Study (IRAS)Diabetologia, 2012
- Role of Adipokines and Other Inflammatory Mediators in Gestational Diabetes Mellitus and Previous Gestational Diabetes MellitusInternational Journal of Endocrinology, 2012
- Gestational Glucose Tolerance and Maternal Metabolic Profile at 3 Years PostpartumObstetrics & Gynecology, 2011
- Mild glucose intolerance in pregnancy and risk of cardiovascular disease: a population-based cohort studyCanadian Medical Association Journal, 2009
- Inflammation Among Women With a History of Gestational Diabetes Mellitus and Diagnosed Diabetes in the Third National Health and Nutrition Examination SurveyDiabetes Care, 2008
- C-reactive protein and features of metabolic syndrome in Brazilian women with previous gestational diabetesDiabetes Research and Clinical Practice, 2007
- C‐reactive protein and metabolic syndrome in women with previous gestational diabetesDiabetes/Metabolism Research and Reviews, 2006
- Progression of Plasminogen Activator Inhibitor-1 and Fibrinogen Levels in Relation to Incident Type 2 DiabetesCirculation, 2006
- Subclinical Inflammation and Vascular Dysfunction in Women with Previous Gestational Diabetes MellitusThe Journal of Clinical Endocrinology & Metabolism, 2005
- Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose IntoleranceDiabetes, 1979